Use of the epidermal growth factor receptor inhibitors gefitinib erlotinib afatinib dacomitinib and icotinib in the treatment of non-small-cell lung cancer: a systematic review

摘要

IntroductionThis systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients—unselected, selected, and molecularly selected—in three treatment settings: first line, second line, and maintenance.